Results 111 to 120 of about 6,789 (241)

Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis [PDF]

, 2014
BACKGROUND & AIMS: A greater understanding of cholestatic disease is necessary to advance diagnostic tools and therapeutic options for conditions such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).
Bell, Lauren N., Chalasani, Naga, Comerford, Megan, Vuppalanchi, Raj, Wulff, Jacob   +4 more
core   +1 more source

Biology of Cholangiocytes: From Bench to Bedside [PDF]

, 2016
Cholangiocytes, the lining epithelial cells in bile ducts, are an important subset of liver cells. They are activated by endogenous and exogenous stimuli and are involved in the modification of bile volume and composition.
���������
core   +1 more source

What the European Reference Network Registry for Rare Liver Diseases Tells Us About Primary Biliary Cholangitis in European Practice

United European Gastroenterology Journal, Volume 13, Issue 10, Page 1851-1852, December 2025.
Marten A. Lantinga
wiley   +1 more source

FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR‐B1‐deficient mice fed a high‐fat and high‐cholesterol diet

Physiological Reports, 2020
Obeticholic acid (OCA) activates the farnesoid X receptor (FXR) to lower circulating total cholesterol (TC) and high density lipoprotein‐cholesterol (HDL‐C) concentrations and to stimulate fecal cholesterol excretion in mice by increasing hepatic SR‐B1 ...
Amar B. Singh, Bin Dong, Fredric B. Kraemer, Jingwen Liu   +3 more
doaj   +1 more source

Revisiting Parenteral Nutrition-Associated Liver Disease (PNALD) [PDF]

, 2017
Parenteral Nutrition-Associated Liver Disease (PNALD) causes progressive cholangitis which can lead to liver failure and cirrhosis especially in infants.
Pullicino, Edgar
core  

The Concise Guide to PHARMACOLOGY 2015/16:Nuclear hormone receptors [PDF]

, 2015
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org),
Aldrich, R, Alexander, SPH, Attali, B, Back, M, Barnes, NM, Bathgate, R, Beart, PM, Becirovic, E, Benson, HE, Biel, M, Birdsall, NJ, Boison, D, Brauner-Osborne, H, Broeer, S, Bryant, C, Burnstock, G, Burris, T, Cain, D, Calo, G, Chan, SL, Chandy, KG, Chiang, N, Christakos, S, Christopoulos, A, Chun, JJ, Chung, J-J, Cidlowski, JA, Clapham, DE, Connor, MA, Coons, L, Cox, HM, Dautzenberg, FM, Davies, JA, Dent, G, Douglas, SD, Dubocovich, ML, Edwards, DP, Faccenda, E, Farndale, R, Fong, TM, Forrest, D, Fowler, CJ, Fuller, P, Gainetdinov, RR, Gershengorn, MA, Goldin, A, Goldstein, SAN, Grimm, SL, Grissmer, S, Gundlach, AL, Hagenbuch, B, Hammond, JR, Hancox, JC, Hartig, S, Hauger, RL, Hay, DL, Hebert, T, Hollenberg, AN, Holliday, ND, Hoyer, D, Ijzerman, AP, Inui, KI, Ishii, S, Jacobson, KA, Jan, LY, Jarvis, GE, Jensen, R, Jetten, A, Jockers, R, Kaczmarek, LK, Kanai, Y, Kang, HS, Karnik, S, Kelly, E, Kerr, ID, Korach, KS, Lange, CA, Larhammar, D, Leeb-Lundberg, F, Leurs, R, Lolait, SJ, Macewan, D, Maguire, JJ, Marrion, N, May, JM, Mazella, J, McArdle, CA, McDonnell, DP, Michel, MC, Miller, LJ, Mitolo, V, Monie, T, Monk, PN, Mouillac, B, Murphy, PM, Nahon, J-L, Nerbonne, J, Nichols, CG, Norel, X, Oakley, R, Offermanns, S, Palmer, LG, Panaro, MA, Pawson, AJ, Perez-Reyes, E, Pertwee, RG, Peters, JA, Pike, JW, Pin, JP, Pintor, S, Plant, LD, Poyner, DR, Prossnitz, ER, Pyne, S, Ren, D, Richer, JK, Rondard, P, Ross, RA, Sackin, H, Safi, R, Sanguinetti, MC, Sartorius, CA, Segaloff, DL, Sharman, JL, Sladek, FM, Southan, C, Stewart, G, Stoddart, LA, Striessnig, J, Summers, RJ, Takeda, Y, Tetel, M, Toll, L, Trimmer, JS, Tsai, M-J, Tsai, SY, Tucker, S, Usdin, TB, Vilargada, J-P, Vore, M, Ward, DT, Waxman, SG, Webb, P, Wei, AD, Weigel, N, Willars, GB, Winrow, C, Wong, SS, Wulff, H, Ye, RD, Young, M, Zajac, J-M   +151 more
core   +4 more sources

Management of primary biliary cholangitis prior to obeticholic acid availability

Minerva Medica, 2018
Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease with unknown etiology. The prognosis of patients affected by PBC is heterogeneous, with a relevant improvement achieved after the introduction of ursodeoxycolic acid (UDCA). Since in the last years obeticholic acid (OCA) has been approved for the combined treatment of PBC, in ...
Durazzo, Marilena, BONETTO, SILVIA, Fagoonee, Sharmila, Morgando, Anna, Pellicano, Rinaldo   +4 more
openaire   +3 more sources

Застосування урсодезоксихолевої кислоти при лікуванні функціональних розладів біліарної системи [PDF]

, 2017
В огляді літератури подані сучасні відомості щодо застосування урсодезоксихолевої кислоти при лікуванні функціональних розладів біліарної системи. Для написання статті здійснювався пошук інформації з використанням баз даних Scopus, Web of Science ...
Бабич, В.Л.
core  

Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? [PDF]

, 2014
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that might affect up to one-third of the adult population in industrialised countries.
Firneisz, Gábor
core   +1 more source

Targeting hepatic glycerolipid synthesis and turnover to treat fatty liver disease [PDF]

, 2014
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of metabolic abnormalities ranging from simple hepatic steatosis (accumulation of neutral lipid) to development of steatotic lesions, steatohepatitis, and cirrhosis.
Finck, Brian N, Schweitzer, George G
core   +3 more sources